Arrakis Therapeutics
PrivateLast Round
Series B
Apr 18, 2019
Total Funding Raised
$115M
Company Overview
Arrakis Therapeutics is a biotechnology company that offers a drug discovery platform aimed at identifying novel therapeutic interventions through the integration of RNA bioinformatics, chemical biology tools, and medicinal chemistry, facilitating treatment for various diseases such as neurology, oncology, and rare genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arrakis Therapeutics Comparables
Compare Arrakis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ribometrix | 94% | |
| Expansion Therapeutics | 90% | |
| Skyhawk Therapeutics | 89% |
Arrakis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 18, 2019 | ||||
| Series A | Feb 27, 2017 | ||||
| Seed | Jul 1, 2015 |
Key People
Founding team and executive leadership
Arrakis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Omega Funds | Series B |
| GV | Series B |
| Advent Life Sciences | Series A, Series B, Seed |
| Osage University Partners | Series A, Series B |
| OrbiMed | Series B |
| HBM Healthcare Investments | Series B |
| Canaan Partners | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2025
Developing RNA-targeted small molecule for Myotonic Dystrophy.
- Mar 10, 2025
Will present RNA-targeted small molecule for Myotonic Dystrophy at MDA Conference 2025.
Arrakis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Arrakis Therapeutics's valuation, stock price, and market status.
Is Arrakis Therapeutics a public or private company?
Arrakis Therapeutics is a private company.
What is the current stock price of Arrakis Therapeutics?
Arrakis Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Arrakis Therapeutics worth (valuation)?
Valuation information for Arrakis Therapeutics is not publicly available.
Can I buy Arrakis Therapeutics stock?
Arrakis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Arrakis Therapeutics's last funding round?
Arrakis Therapeutics's most recent funding round was Series B on April 18, 2019.
Who are the main investors in Arrakis Therapeutics?
Key investors in Arrakis Therapeutics include Canaan Partners, Nextech Invest.
Will Arrakis Therapeutics IPO soon?
No public IPO plans have been announced for Arrakis Therapeutics.
How can I track Arrakis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Arrakis Therapeutics's secondary market activity and sign up for updates.